Endopredict Publications
2020
Sep 2020
Prognostic value of EndoPredict in women with hormone receptor-positive, HER2-negative invasive lobular breast cancer.
Sestak I, Filipits M, Buus R, Rudas M, Balic M, Knauer M, Kronenwett R, Fitzal F, Cuzick J, Gnant M, Greil R, Dowsett M, Dubsky P.
Clin Cancer Res 26(17):4682-4687, 2020
https://pubmed.ncbi.nlm.nih.gov/32561662/
June 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, and Filipits on behalf of the Austrian Breast Colorectal Cancer Study Group.
European Journal of Cancer 134:99-106, 2020
https://www.ejcancer.com/article/S0959-8049(20)30223-9/fulltext
May 2020
EndoPredict in early hormone receptor-positive, HER2-negative breast cancer.
Almstedt K, Mendoza S, Otto M, Battista MJ, Steetskamp J, Heimes AS, Krajnak S, Poplawski A, Gerhold-Ay A, Hasenburg A, Denkert C, Schmidt M.
Breast Cancer Res Treat. 182:237-146, 2020
https://link.springer.com/article/10.1007/s10549-020-05688-1
April 2020
Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
Jahn SW, Bosl A, Tsybrovskyy O, Gruber-Rossipal C, Helfgott R, Fitzal F, Knauer M, Balic M, Jasarevic Z, Offner F, Moinfar F.
Br J Cancer 122:1744-1746, 2020
https://www.nature.com/articles/s41416-020-0838-2
Mar 2020
Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of mexican premenopausal breast cancer patients.
Villareal-Garza C, Lopez-Martinez EA, Deneken-Hernandez Z, Maffuz-Aziz A, Munoz-Lozano JF, Barragan-Carrillo R, Ramos-Elias P, Moreno B, Diaz-Perez H, Pena-Curiel O, Curiel-Valdez, JdJ, Bautista-Pina V.
PLoS One. 15(3):e0228884, 2020
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228884
Jan 2020
Retrospective cost-analysis of the EndoPredict test in patients with primary breast cancer in a German breast center.
Neusser S, Philipp L, Schlake G, Neumann A, Tonnies P, Wilhelms S, Petry C, Kronenwett R, Wasem J, Schlake W, Biermann-Stallwitz J
Journal of Public Health: From Theory to Practice 2020
https://link.springer.com/article/10.1007/s10389-020-01193-3
Jan 2020
Evaluation of the 12-Gene molecular score and the 21-gene recurrence score as predictors of response to neo-adjuvant chemotherapy in estrogen receptor-positive, HER2-negative breast cancer.
Soliman H, Wagner S, Flake DD, Robson M, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster JM, Lanchbury JS, Gutin A, Gradishar W.
Annals of Surgical Oncology. 27(3):765-771, 2020
https://link.springer.com/article/10.1245%2Fs10434-019-08039-7
2019
Dec 2019
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EPclin) use (UCBG 2-14).
Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, Leheurteur M, Uwer L, Derbel O, Le Rol A, Jacquin JP, Jouannaud C, Quenel-Tueux N, Girre V, Foa C, Guardiola E, Lortholary A, Catala S, Guiu S, Valent A, Boinon D, Lemonnier J, Delaloge S.
Breast. 49:132-40, 2020
https://www.sciencedirect.com/science/article/pii/S0960977619305843?via%3Dihub
Aug 2019
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.
Soliman H, Flake II DD, Magliocco A, Robson M, Schwartzberg L, Sharma P, Brown K, Wehnelt S, Kronenwett R, Gutin A, Lancaster J, Cuzick J, Gradishar W.
JCO Precis Oncol 2019 [Epub ahead of print]
https://ascopubs.org/doi/10.1200/PO.18.00361
May 2019
Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer C, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster J, Fitzal F, Gnant M.
Clin Cancer Res. 2019;25:3865-72.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Prediction+of+Distant+Recurrence+using+EndoPredict+among+Women+with+ER%2B%2C+HER2-+Node-+Positive+and+Node-Negative+Breast+Cancer+Treated+with+Endocrine+Therapy+Only.
Apr 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak I, Martin M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodriguez A, Gnant M.
Breast Cancer Res Treat. 2019; 176:377-86.
https://www.ncbi.nlm.nih.gov/pubmed/31041683
2018
Dec 2018
RESCUE: REACHING FOR EVIDENCE-BASED CHEMOTHERAPY USE IN ENDOCRINE SENSITIVE BREAST CANCER, A prospective health care study on risk assessment by the clinicomolecular test EndoPredict® and long-term patient outcome in early luminal breast cancer.
Ettl J, Blohmer J-U, Denkert C, Keller M, Klein E, Kronenwett R, Neuser P, Paepke S, Schade-Brittinger C, Schnuppe K, Untch M, Wittenberg M, Kiechle M.
Poster: SABCS 2018; OT1-12-03.
https://cancerres.aacrjournals.org/content/79/4_Supplement/OT1-12-03
Dec 2018
Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.
Villarreal-Garza C, Deneken-Hernandez Z, Maffuz-Aziz A, Lopez-Martinez EA, Muñoz-Lozano JF, Barragan-Carrillo R, Peña-Curiel O, Moreno-Jaime B, Ramos-Elias P, Diaz H, Bautista-Piña V, Garcia-Garcia M, Mesa-Chavez F.
Poster: SABCS 2018; P2-08-54.
https://cancerres.aacrjournals.org/content/79/4_Supplement/P2-08-54
Dec 2018
EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures.
Lacroix-Triki M, Arnould L, MacGrogan G, Penault-Llorca F, Haudebourg J, Tas P, Garnier A, Vincent-Salomon A, Miquel C, Lehmann-Che J, Callens C, Quillien V, Cayre A, Lamy PJ, Rouleau E, de Cremoux P.
Poster: SABCS 2018; P4-08-23.
https://cancerres.aacrjournals.org/content/79/4_Supplement/P4-08-23
Jul 2018
Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor.
Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner BM, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C.
Clin Cancer Res. 2018;24:3358-65.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Risk+assessment+after+neoadjuvant+chemotherapy+in+luminal+breast+cancer+using+a+clinicomolecular+predictor.
Jun 2018
Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.
Gradishar W, Robson M, Flake II DD, Schwartzberg L, Sharma P, Soliman H, Magliocco A, Brown K, Wehnelt S, Gutin A, Kronenwett R, Lancaster J.
Abstract: J Clin Oncol 36, 2018 (suppl; abstr 525).
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.525
